Date
- 2026 (41)
- 2025 (31)
- 2024 (17)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (46)
- 2017 (11)
- 2016 (44)
- 2015 (36)
- 2014 (10)
- 2013 (12)
- 2012 (3)
- 2011 (6)
- 2010 (27)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (10)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (3)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (3)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (12)
Sponsor content
592 result(s) found, displaying 11 to 20
-
Prescription medicine decision summaryTabrecta has been approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation. Tabrecta contains the active ingredient capmatinib.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)Rhapsido (remibrutinib) has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 150 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 200mg capsules blister pack.
-
Prescription medicine registrationActive ingredients: lutetium (177Lu) vipivotide tetraxetan.
-
Prescription medicine registrationActive ingredients: capmatinib hydrochloride.
-
Jun-2026Prescription medicine evaluationActive ingredient: Secukinumab.
-
Prescription medicine decision summaryRhapsido has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido contains the active ingredient remibrutinib.